Journal Article (Erratum/Correction)

DZNE-2023-01159

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial

Mummery, C. J. ; Börjesson-Hanson, A. ; Blackburn, D. J. ; Vijverberg, E. G. B. ; De Deyn, P. P. ; Ducharme, S. ; Jonsson, M. ; Schneider, A.DZNE* ; Rinne, J. O. ; Ludolph, A. C.DZNE* ; Bodenschatz, R. ; Kordasiewicz, H. ; Swayze, E. E. ; Fitzsimmons, B. ; Mignon, L. ; Moore, K. M. ; Yun, C. ; Baumann, T. ; Li, D. ; Norris, D. A. ; Crean, R. ; Graham, D. L. ; Huang, E. ; Ratti, E. ; Bennett, C. F. ; Junge, C. ; Lane, R. M.

2024
Nature America Inc. New York, NY

This record in other databases:    

Please use a persistent id in citations: doi:10.1038/s41591-023-02639-3

---

Contributing Institute(s):

1. Translational Dementia Research (Bonn) (AG Schneider)
2. Clinical Study Center Ulm (Clinical Study Center Ulm)

Research Program(s):

1. 352 - Disease Mechanisms (POF4-352) (POF4-352)
2. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2024

---

Database coverage:
; ; ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; DEAL Nature ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 80 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---

---

Linked articles:

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Journal Article Mummery, C. J. ; Börjesson-Hanson, A. ; Blackburn, D. J. ; Vijverberg, E. G. B. ; De Deyn, P. P. ; Ducharme, S. ; Jonsson, M. ; Schneider, A.DZNE* ; Rinne, J. O. ; Ludolph, A. C.DZNE* ; Bodenschatz, R. ; Kordasiewicz, H. ; Swayze, E. E. ; Fitzsimmons, B. ; Mignon, L. ; Moore, K. M. ; Yun, C. ; Baumann, T. ; Li, D. ; Norris, D. A. ; Crean, R. ; Graham, D. L. ; Huang, E. ; Ratti, E. ; Bennett, C. F. ; Junge, C. ; Lane, R. M.
Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.
Nature medicine 29(6), 1437-1447 (2023) [10.1038/s41591-023-02326-3]2023   Files  Fulltext Fulltext by Pubmed Central BibTeX | EndNote: XML, Text | RIS

---